RT Journal Article
T1 Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
A1 Fraile-Ribot, Pablo A.
A1 Zamorano, Laura
A1 Orellana, Rocio
A1 Del Barrio-Tofiño, Ester
A1 Sanchez-Diener, Irina
A1 Cortes-Lara, Sara
A1 Lopez-Causape, Carla
A1 Cabot, Gabriel
A1 Bou, German
A1 Martinez-Martinez, Luis
A1 Oliver, Antonio
K1 Pseudomonas aeruginosa
K1 Antibiotic resistance
K1 Extensively drug resistant
K1 Imipenem-relebactam
K1 Multidrug resistance
K1 Whole-genome sequencing
K1 β-lactam resistance mechanisms
AB Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.
PB ASM Journals
YR 2019
FD 2019-11-14
LK http://hdl.handle.net/10668/14708
UL http://hdl.handle.net/10668/14708
LA en
NO Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, et al. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19
NO The following are members of GEMARA-SEIMC/REIPI Pseudomonas study group: Fátima Galán, Irene Gracia, Manuel Antonio Rodríguez, Lina Martín, Juan Manuel Sánchez, Laura Viñuela, Ma Victoria García, José Antonio Lepe, Javier Aznar, Inma López-Hernández, Cristina Seral, Francisco Javier Castillo-García, Ana Isabel López Calleja, Carmen Aspiroz, Pedro de la Iglesia, Susana Ramón, Elena Riera, María Cruz Pérez, Carmen Gallegos, Jorge Calvo, María Dolores Quesada, Francesc Marco, Yannick Hoyos, Juan Pablo Horcajada, Nieves Larrosa, Juan José González, Fe Tubau, Silvia Capilla, Mar Olga Pérez-Moreno, Ma José Centelles, Emma Padilla, Alba Rivera, Beatriz Mirelis, Raquel Elisa Rodríguez-Tarazona, Noelia Arenal-Andrés, María del Pilar Ortega, Gregoria Megías, Inmaculada García, Cristina Colmenarejo, José Carlos González, Nora Mariela Martínez, Bárbara Gomila, Salvador Giner, Nuria Tormo, Eugenio Garduño, José Andrés Agulla, Alejandro Seoane, Julia Pita, Isabel Paz Vidal, David Mauricio Guzmán, Marta García, María Luisa Pérez del Molino, Gema Barbeito, Fernando Artiles, José Manuel Azcona-Gutiérrez, Yolanda Sáenz, José Antonio Oteo, Ana González, Jennifer Villa, Fernando Chaves, Emilia Cercenado, Teresa Alarcón, Nelly Daniela Zurita, Irene Merino, María Isabel Morosini, Rafael Cantón, María Isabel Sánchez, Laura Moreno, Genoveva Yagüe, José Leiva, José Luis Barrios, Andrés Canut, and Jesús Oteo. We thank the students Adela Reus, Sergi Martorell, and Miquel Àngel Sastre for collaboration in the susceptibility testing studies.The work was supported by MSD and by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and grant PI18/00076 cofinanced by European Regional Development Fund (ERDF) “A way to achieve Europe,” Operative Program Intelligent Growth 2014 –2020. The work was partially financed by MSD through Investigator Initiated Studies Program to A.O. The funders had no role in design, execution, analysis, or reporting of the research.
DS RISalud
RD Apr 6, 2025